Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

Rhea-AI Summary

Onconova Therapeutics, Inc. (NASDAQ: ONTX) will release its second quarter 2022 financial results on August 11, 2022. Following the results announcement, management will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and updates on clinical pipeline programs. Investors can join the call or access it via the company's website. Onconova focuses on developing targeted anti-cancer agents, with ongoing Phase 1 studies for its multi-kinase inhibitor, narazaciclib, in the U.S. and China, along with an investigator-sponsored study for rigosertib.

Positive

• Ongoing Phase 1 studies for narazaciclib in the U.S. and China.
• Investigator-sponsored study for rigosertib shows active development.

Negative

• None.

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022

NEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its second quarter 2022 financial results on Thursday, August 11, 2022. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs.

Conference Call and Webcast Information

Interested parties who wish to participate in the conference call may do so by dialing (800) 289-0571 for domestic and (856) 344-9290 for international callers and using conference ID 3600715.

Those interested in listening to the conference call via the internet may do so by visiting the investors and media page on the Company's website at www.onconova.com and clicking on the webcast link. In addition to the live webcast, a replay will be available on the Onconova website for 90 days following the call.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

When will Onconova report its second quarter 2022 financial results?

Onconova will report its second quarter 2022 financial results on August 11, 2022.

What time is Onconova's conference call on August 11, 2022?

The conference call will take place at 4:30 p.m. Eastern Time on August 11, 2022.

How can I access Onconova's conference call?

You can access it by dialing (800) 289-0571 for domestic calls or (856) 344-9290 for international calls, using conference ID 3600715, or by visiting Onconova's website.

What is the focus of Onconova's clinical pipeline?

Onconova's clinical pipeline focuses on discovering and developing novel anti-cancer agents, including narazaciclib and rigosertib.